Jun 24, 2019 9:00 am EDT Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
Jun 4, 2019 9:15 am EDT Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
May 23, 2019 5:00 pm EDT Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer
May 21, 2019 7:30 am EDT Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
May 15, 2019 7:55 am EDT Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel
Apr 24, 2019 8:00 am EDT Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
Apr 15, 2019 9:15 am EDT Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
Apr 1, 2019 9:20 am EDT Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal